Drug intelligence / Profile preview

PD-1601

Development stage: Preclinical
Lead developer: BioArctic
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous, Intrathecal

Overview

PD-1601 is a monoclonal antibody developed by BioArctic that targets α-synuclein, a protein implicated in the pathogenesis of Parkinson's disease and other neurodegenerative disorders. As an α-synuclein inhibitor, its mechanism of action involves binding to and inhibiting α-synuclein, potentially reducing or preventing the aggregation of this protein that leads to neuronal dysfunction. The drug is being investigated primarily for nervous system diseases, with Parkinson's disease as a key indication. As of March 2025, PD-1601 remains in the discovery phase and has not yet entered clinical trials[1][4].

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on PD-1601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-1601.

Explore the full profile